Research tool page — not in the public editorial index
This company can still be explored inside Wall Street Score, but this URL remains noindex and is not eligible for Google-served ads until source-specific publisher curation is documented and the public research-quality checks pass.
Biofrontera Inc.
BFRI · Price history
Price at last available close
$0.91
−$0.17 (-16.03%) 1M
2026-10-30
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Biofrontera Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
How they make money
Biofrontera Inc. generates revenue primarily by selling its pharmaceutical products, specifically Ameluz and the RhodoLED lamp series, directly to dermatology offices and medical groups in the United States through its national commercial sales team.
Products & services
The company markets Ameluz (aminolevulinic acid hydrochloride) for photodynamic therapy and the RhodoLED and RhodoLED XL lamp series for the treatment of actinic keratosis.
Brands & revenue mix
Prescription drug for photodynamic therapy.
Separate brand revenue is not available in this research.Source
Lamp series used for photodynamic therapy.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
For the year ended December 31, 2025, no customer represented more than 10% of net revenues.
Suppliers, materials & equipment
- Biofrontera Group — The company relies on the Biofrontera Group as a supplier for its products, including Ameluz and the RhodoLED lamps.Source
Strengths
- National commercial sales teamSource
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
10
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
25
Poor
Financial Strength
38
Business Quality / Moat
17
Management
0
Growth Quality
65
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Asset quality scores strongly
- •Share split detected
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •CRITICAL: Bankruptcy / liquidation risk
- •Debt service risk
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for BFRI
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can BFRI maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can BFRI fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does BFRI's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for BFRI to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BFRI's current valuation?
Essential Investment Snapshot
Wall Street Score
10
Market Cap
$13.2M
P/E Ratio
-1.8
EPS
$-0.60
52-Week High
$1.66
52-Week Low
$0.55
Beta
0.84
Shares Outstanding
11.6M
Total Revenue
$46.2M
Total Debt
$7.5M
Dividend
No current dividend
Liquidation Value / Share
$0.51
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BFRI
Detected from reported data — verify before acting.Share split detected
A recent SEC filing references a reverse stock split/share consolidation. Repeated reverse splits receive progressively harsher score ceilings.
Supporting sourceMAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingDebt service risk
Interest coverage is low (~-20.2x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on BFRI.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +National commercial sales team.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Pharmaceuticals industry.
- −Reliance on a single supplier for key products.
- −Dependence on the commercial success of Ameluz and RhodoLED.
- −A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
22
Sep 9, 2026
Change
-11.9
points
Current Score
10
Oct 1, 2026
Category Changes
BFRI decreased 11.9 points because some fundamentals weakened.
Positive Contributors
- + Asset improved by 8.7 points
Projected Score
Projected Score
5
Projected Change
-4.8 points
Preliminary comparable-period financial changes suggest decline of approximately 4.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.89
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $46.2M | $41.7M | $37.3M | $34.1M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $7.2M | $8.9M | $18.6M | $17.4M | ···· | ···· | ···· | ···· |
| Gross Profit | $39.0M | $32.8M | $18.7M | $16.6M | ···· | ···· | ···· | ···· |
| Research & Development | $3.0M | $3.7M | $2.1M | $77K | ···· | ···· | ···· | ···· |
| SG&A Expenses | $39.7M | $38.1M | $33.8M | $39.1M | ···· | ···· | ···· | ···· |
| Operating Expenses | $43.4M | $42.0M | $35.9M | $39.3M | ···· | ···· | ···· | ···· |
| EBITDA | -$5.6M | -$9.2M | -$14.4M | -$18.5M | ···· | ···· | ···· | ···· |
| Operating Income | -$4.4M | -$9.1M | -$17.2M | -$22.7M | ···· | ···· | ···· | ···· |
| Interest Expense | $232K | $452K | $2.1M | $600K | ···· | ···· | ···· | ···· |
| Income Before Tax | -$6.3M | -$10.5M | -$17.7M | -$20.1M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $29K | $25K | $22K | $14K | ···· | ···· | ···· | ···· |
| Net Income | -$6.4M | -$10.5M | -$17.8M | -$20.1M | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.60 | $-1.04 | $-3.22 | $-13.02 | ···· | ···· | ···· | ···· |
| Basic Shares | 12.92M | 10.17M | 5.52M | 1.55M | ···· | ···· | ···· | ···· |
| Diluted Shares | 12.92M | 11.65M | 5.52M | 1.55M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$12.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.05
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+50.0%
Cash Change
-35.6%
Margin Change
+53.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
What Weakened
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, net income margin. Pressure indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 32.9%. EPS declined 91.2%. Cash declined 35.6%. Total debt increased 50.0%. Net income margin improved by 53.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - PharmaceuticalsNews
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
Rumor Mill · BFRI
Corporate developments & opportunities
No reviewed developments match this filter.
The reliability percentage measures the strength of the supporting evidence—not the probability that the event will occur or that the stock will rise. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial